Northway Biotech Opens €61M Cell Therapy and Personalized Medicine CDMO in Vilnius, Marking Baltic Region’s First

September 6, 2026

PR Newswire Lithuania

Overview

Northway Biotech has launched a pioneering €61 million ($65M USD) cell therapy and personalized medicine CDMO facility in Vilnius, Lithuania, establishing the first such hub in the Baltics. This 3,500-square-meter plant features up to 20 cGMP manufacturing lines, significantly expanding capabilities for advanced biopharmaceuticals, gene therapies, and cell-based technologies, with initial customer programs already underway. Its strategic opening addresses critical market demand for complex biomanufacturing and positions the region as a growing center for life sciences innovation.

In Depth

Key Findings

Northway Biotech has inaugurated a pioneering €61 million (approximately $65 million USD) cell therapy and personalized medicine Contract Development and Manufacturing Organization (CDMO) facility in Vilnius, Lithuania. This state-of-the-art 3,500-square-meter facility marks a significant milestone as the first of its kind in the Baltic region, poised to dramatically enhance biomanufacturing capabilities and contribute significantly to the advancement of the cell and gene therapy sector across Europe. With up to 20 independent cGMP manufacturing lines designed for a wide range of modalities, including advanced cell-based technologies, gene therapies, and personalized vaccines, the immediate securing of multiple customer programs underscores the high demand and strategic value of this new biomanufacturing hub.

Technical Specifications and Capabilities

Facility Size and Capacity: The new facility spans 3,500 square meters and is equipped with cutting-edge infrastructure. It is capable of accommodating up to 20 independent cGMP (current Good Manufacturing Practice) manufacturing lines, enabling the concurrent production of various cell therapy and personalized medicine products at scale.
Broad Modality Support: This CDMO is meticulously designed to support a wide range of modalities, including mammalian and microbial biopharmaceuticals, gene therapy products, and cell-based technologies (both autologous and allogeneic cell therapies). Furthermore, it is equipped to facilitate the development and manufacturing of personalized therapeutic vaccines and advanced 3D human tissue technologies.
High-Level Quality Standards: The manufacturing environment strictly adheres to cGMP standards, which is essential for ensuring the consistency of safety, purity, and potency of cell therapy products. The facility’s design meets the latest regulatory requirements, thereby supporting accelerated approval processes.
Contribution to Personalized Medicine: Dedicated lines for autologous cell therapies, personalized vaccines, and 3D tissue technologies enable the production of personalized medicine products tailored to individual patient needs. This offers groundbreaking treatment options for diseases with limited existing therapies, such as cancer and rare diseases.
Role as a Regional Hub: As the first facility of its kind in the Baltics, it is set to act as a hub for biotechnology innovation, fostering the development of the life sciences ecosystem in the region and attracting further investment and talent.

Background & Context

The cell and gene therapy sector is experiencing rapid growth, leading to a global surge in demand not only for therapeutic development but also for specialized CDMO infrastructure to manufacture these complex products. The manufacturing of cell therapies, in particular, requires highly specialized technologies and stringent quality control, making it a challenging area for many pharmaceutical companies to manage in-house. Northway Biotech’s investment directly addresses this critical market gap, signifying a strategic expansion of cell therapy manufacturing capacity in Europe, especially within the burgeoning Baltic region.

Strategic Significance & Outlook

Northway Biotech’s new CDMO facility is expected to play a crucial role in accelerating the commercialization of cell and gene therapy products, bringing innovative treatments to a broader patient population. The 20 independent manufacturing lines provide high flexibility, capable of supporting diverse projects from early-stage development programs to late-stage clinical trials and commercial-scale production. This investment positions Lithuania as a significant player on Europe’s biotechnology map, promising a substantial impact on regional research and development, enhances advanced manufacturing capabilities, and is expected to generate significant job growth within the life sciences sector. Industry stakeholders, including investors, engineers, and pharmaceutical companies, are advised to closely monitor the emerging manufacturing partnerships and market opportunities that this development is poised to create.

Source: https://www.prnewswire.com/news-releases/first-in-the-baltics-northway-biotech-opens-61-million-cell-therapy-and-personalized-medicine-cdmo-in-vilnius-302868969.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.